Opinion|Videos|March 6, 2025
Sequencing Through Multiple Lines of Therapy for mRCC
Author(s)Sumanta Kumar Pal, MD
A panelist discusses how treatment sequencing decisions in RCC span multiple lines of therapy, incorporating various options like tivozanib, lenvatinib-everolimus combinations, and belzutifan, with careful consideration given to optimal dosing strategies, expected duration of therapy, anticipated response patterns, and the specific timing of each agent in the treatment journey, particularly in the post-ICI setting.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How are you sequencing these agents through multiple lines of therapy?
- Thinking beyond the patient case just reviewed, please discuss your preferred subsequent-line after a first-line ICI + ICI regimen?
- Would you have followed the sequence of therapies used for the patient described in this case?
- Are you using tivozanib in the second-line setting? If yes, in which patients?
- Are you using lenvatinib + everolimus in the post-ICI setting? If yes, in what line of therapy?
- How do you approach dosing? How long to you expect your patients to remain on therapy? What type of responses do you expect (depth, duration)?
- How are you using belzutifan in your practice?
Advertisement
Related to this article
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer
4
Dr Beck on the Practical Realities of Subcutaneous Oncology Drug Delivery
5